Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-383 in Advanced or Metastatic Solid Tumors
NCT07030257Phase 2Recruiting
- Sponsor
- Tasca Therapeutics
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CP-383 in Solid tumor malignancy, colorectal carcinoma (CRC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), bladder cancer, sponsored by Tasca Therapeutics. Started Aug 2025; status: recruiting.
02
Drugs
CP-383
03
Conditions
Solid tumor malignancycolorectal carcinoma (CRC)small cell lung cancer (SCLC)head and neck squamous cell carcinoma (HNSCC)bladder cancer
Beyond the preview
Go deeper on NCT07030257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030257.